Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Goldenwell Biotech (GWLL) EBITDA Margin (2021 - 2024)

Goldenwell Biotech filings provide 4 years of EBITDA Margin readings, the most recent being 45674.05% for Q4 2024.

  • On a quarterly basis, EBITDA Margin fell 3767444.0% to 45674.05% in Q4 2024 year-over-year; TTM through Sep 2025 was 35406.33%, a 1131961.0% decrease, with the full-year FY2024 number at 19853.96%, down 1851158.0% from a year prior.
  • EBITDA Margin hit 45674.05% in Q4 2024 for Goldenwell Biotech, down from 34402.88% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 2261.3% in Q2 2021 to a low of 45674.05% in Q4 2024.
  • Median EBITDA Margin over the past 4 years was 5181.45% (2023), compared with a mean of 9772.08%.
  • Biggest five-year swings in EBITDA Margin: surged 604653bps in 2023 and later crashed -3767444bps in 2024.
  • Goldenwell Biotech's EBITDA Margin stood at 133.52% in 2021, then soared by 92bps to 10.49% in 2022, then tumbled by -76144bps to 7999.62% in 2023, then crashed by -471bps to 45674.05% in 2024.
  • The last three reported values for EBITDA Margin were 45674.05% (Q4 2024), 34402.88% (Q2 2024), and 7999.62% (Q4 2023) per Business Quant data.